MediPharm Labs Corp. (TSXV:LABS) (the “Company” or “MediPharm Labs”), a specialised, analysis pushed hashish extraction enterprise licensed below the Cannabis Act, is happy to announce its addition to the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) (“HMMJ” or “ETF”).
MediPharm Labs Corp. (TSXV:LABS) (the “Company” or “MediPharm Labs”), a specialised, analysis pushed hashish extraction enterprise licensed below the Cannabis Act, is happy to announce its addition to the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) (“HMMJ” or “ETF”). The addition of MediPharm to the HMMJ Index is a big milestone and one other vital step within the Company’s evolution as a frontrunner in purified hashish extraction.
HMMJ is an index (or passively managed) ETF, which seeks to replicate, to the extent doable, the efficiency of the North American Marijuana Index, internet of bills. This index is designed to present publicity to the efficiency of a basket of North American publicly listed life sciences corporations with important enterprise actions within the Marijuana trade. The North American Marijuana Index selects from a present universe of corporations which have operations that will embrace a number of of biopharmaceuticals, medical manufacturing, distribution, bio-products and different ancillary companies associated to the Marijuana trade.
Rebalancing of the North American Marijuana Index, and consequently HMMJ, happens every calendar quarter. At that time, all shares eligible for inclusion are weighted by their respective market capitalization. However, no single stock can exceed a 10% weight of the North American Marijuana Index on the rebalance date. The holdings of HMMJ and its present portfolio weights are frequently up to date and out there at www.HorizonsETFs.com/HMMJ.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs is a pioneer within the hashish trade and has the excellence of being the primary firm in Canada to grow to be a licensed producer for hashish oil manufacturing below the Access to Cannabis for Medical Purposes Regulations (ACMPR) with out first receiving a hashish cultivation licence. This knowledgeable give attention to hashish concentrates from its cGMP (present Good Manufacturing Practices) and ISO standard-built clear rooms and demanding environments laboratory, permits MediPharm Labs to work with its established, Health Canada-approved cultivation companions to produce pharmaceutical-grade hashish oil with a competitive benefit. MediPharm Labs is research-driven and targeted on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs gives B2B contract processing of hashish to Canadian licensed licensed producers and acceptable worldwide growers, supplying integrity-assured hashish oil to certified corporations on the market below their very own model. In addition, MediPharm Labs will provide uncooked supplies, formulations, processing and packaging for the creation of ready-to-sell superior by-product merchandise. MediPharm Labs was awarded Start-Up Of The Year on the current Canadian Cannabis Awards hosted by Lift & Co.
Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has additionally accomplished its utility course of with the federal Office of Drug Control to extract and import medical hashish merchandise in Australia.
|For additional data, please contact:|
|Laura Lepore, Vice President, Investor Relations & Communications|
|Telephone:||705-719-7425 ext 216|
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This information launch comprises “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) inside the that means of the relevant Canadian securities laws. All statements, aside from statements of historic truth, are forward-looking statements and are primarily based on expectations, estimates and projections as on the date of this information launch. Any assertion that includes discussions with respect to predictions, expectations, beliefs, plans, projections, targets, assumptions, future occasions or efficiency (typically however not all the time utilizing phrases resembling “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such phrases and phrases or stating that sure actions, occasions or outcomes “may” or “could”, “would”, “might” or “will” be taken to happen or be achieved) should not statements of historic truth and could also be forward-looking statements. In this information launch, forward-looking statements relate to, amongst different issues, anticipated GMP certification and the institution of operations in Australia. Forward-looking statements are essentially primarily based upon quite a few estimates and assumptions that, whereas thought-about affordable, are topic to identified and unknown dangers, uncertainties, and different components which can trigger the precise outcomes and future occasions to differ materially from these expressed or implied by such forward-looking statements. Such components embrace, however should not restricted to: basic enterprise, financial, competitive, political and social uncertainties; the shortcoming of MediPharm to receive sufficient financing; and the delay or failure to obtain regulatory approvals. There might be no assurance that such statements will show to be correct, as precise outcomes and future occasions might differ materially from these anticipated in such statements. Accordingly, readers mustn’t place undue reliance on the forward-looking statements and knowledge contained on this information launch. Except as required by regulation, MediPharm assumes no obligation to replace the forward-looking statements of beliefs, opinions, projections, or different components, ought to they alter.